Lexeo director granted 35,000 stock options

Lexeo Therapeutics, Inc. director Paula H. Cholmondeley reported receiving a stock option grant covering 35,000 shares of common stock.

Rhea-AI Filing Summary

Lexeo Therapeutics, Inc. director Paula H. Cholmondeley reported receiving a stock option grant covering 35,000 shares of common stock. The option has an exercise price of $4.7000 per share and expires on June 24, 2036. According to the disclosure, all 35,000 underlying shares will vest and become exercisable on the earlier of one year after the grant date or the next annual meeting of stockholders, provided she continues in service through that date.

Insider Trade Summary

Grant/Award: 35,000 shares

Grant/Award 1 txn

Insider CHOLMONDELEY PAULA H

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	35,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 35,000 contracts (Direct)

Footnotes (1)

1. F1. 100% of the shares underlying the option shall vest, and become exercisable, on the earlier of one year following the grant date or the next annual meeting of stockholders, subject to the Reporting Person's continuous service on such date.

Key Figures

Options granted: 35,000 options Exercise price: $4.7000 per share Underlying shares: 35,000 shares +2 more

5 metrics

Options granted 35,000 options Stock Option (right to buy) grant to director

Exercise price $4.7000 per share Stock option strike price for underlying common stock

Underlying shares 35,000 shares Common stock underlying the granted options

Expiration date June 24, 2036 Option term end date

Post-transaction derivative holdings 35,000 options Total options held following this grant

Key Terms

Stock Option (right to buy), Grant, award, or other acquisition, underlying security, vesting, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

underlying security financial

"underlying_security_title: Common Stock"

vesting financial

"100% of the shares underlying the option shall vest, and become exercisable"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

exercise price financial

"conversion_or_exercise_price: 4.7000"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Lexeo Therapeutics (LXEO) disclose?

Lexeo Therapeutics disclosed that director Paula H. Cholmondeley received a stock option grant for 35,000 shares of common stock at an exercise price of $4.7000 per share, expiring on June 24, 2036.

Who is the reporting person in the Lexeo Therapeutics (LXEO) Form 4?

The reporting person is Paula H. Cholmondeley, a director of Lexeo Therapeutics, Inc. The Form 4 shows a grant of stock options, not an open-market purchase or sale of common shares, and reflects a compensation-related equity award.

How many Lexeo Therapeutics (LXEO) options were granted and at what price?

Paula H. Cholmondeley was granted stock options on 35,000 shares of Lexeo Therapeutics common stock with an exercise price of $4.7000 per share. These options represent the right to buy shares at that fixed price once vested.

When do Paula H. Cholmondeley’s Lexeo Therapeutics (LXEO) options vest?

The options vest 100% on the earlier of one year after the grant date or the next annual meeting of stockholders. Vesting is conditioned on Ms. Cholmondeley’s continuous service with Lexeo Therapeutics through that vesting date.

What is the expiration date of the Lexeo Therapeutics (LXEO) stock options?

The disclosed stock options expire on June 24, 2036. After that date, Paula H. Cholmondeley will no longer be able to exercise the right to purchase Lexeo Therapeutics common stock at the $4.7000 exercise price.

Did the Lexeo Therapeutics (LXEO) director buy or sell common shares in this Form 4?

The Form 4 reports a grant of derivative securities, specifically stock options, rather than a market transaction in common shares. It shows an acquisition of options as compensation, not a buy or sell of existing common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/29/2026 - 04:40 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

CHOLMONDELEY PAULA H

(Last) (First) (Middle)

C/O LEXEO THERAPEUTICS, INC.

345 PARK AVENUE SOUTH, FLOOR 6

(Street)

NEW YORK NEW YORK 10010

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Lexeo Therapeutics, Inc. [ LXEO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/25/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$4.7	06/25/2026		A		35,000		(1)	06/24/2036	Common Stock	35,000	$0	35,000	D

Explanation of Responses:

1. 100% of the shares underlying the option shall vest, and become exercisable, on the earlier of one year following the grant date or the next annual meeting of stockholders, subject to the Reporting Person's continuous service on such date.

	/s/ Youjin Choi, Attorney-in-Fact	06/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)